drugset
drugset / Trial / NCT06494371

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

NCT06494371 ↗

Phase 1 Recruiting 32 enrolled Ruijin Hospital Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed/refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.

Timeline

Start
2024-07
Primary completion
2026-05
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LCAR-HL30 Unknown — Other

Indications

Hodgkins lymphoma anaplastic large cell lymphoma